Company

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot
Foreseen BiotechnologyGeneScience Pharmaceutical

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China's National Medical Products Administration (NMPA) has approved the…

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerCDE

Teligene’s TL118 Enters NMPA’s SPARK Initiative for Pediatric Cancer Treatment Development

FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline

NASDAQ: SNYPriority reviews

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China
AmgenBeiGene

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Show More